Other Key Words::
Number of included patients:
Br J Cancer. 2009 Feb 10;100(3):450-4. Epub 2009 Jan 20.
Association between serum 25(OH)D and death from prostate cancer.
Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE.
The Cancer Registry of Norway, Institute of Population-based Cancer Research, Oslo, Norway.
on observations that for certain cancers, mortality varies according to
sun exposure, vitamin D has been proposed to influence on disease
progression. This study aims to investigate whether serum levels of
25(OH)D are associated with prognosis in patients with prostate cancer.
In total, 160 patients with a serum sample in the JANUS serum bank were
For 123 patients a pre-treatment serum sample was taken,
whereas 37 of the patients had received hormone therapy prior to the
blood collection. The serum level of 25(OH)D was classified as low
(<50 nmol l(-1)), medium (50-80 nmol l(-1)) or high (>80 nmol
l(-1)). A Cox proportional hazard regression model was used to assess
the association between serum 25(OH)D and cancer mortality.
follow-up, 61 deaths occurred, of whom 52 died of prostate cancer. The
median time of follow-up was 44.0 months (range, 1.2-154.6). Serum
25(OH)D at medium or high levels were significantly related to better
prognosis (RR 0.33; 95% CI 0.14-0.77, RR 0.16; 95% CI 0.05-0.43)
compared with the low level.
Analysis restricted to patients receiving
hormone therapy gave a stronger association. The serum level of 25(OH)D
may be involved in disease progression and is a potential marker of
prognosis in patients with prostate cancer.